{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:45:45Z","timestamp":1780656345166,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.pan.2024.09.010","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T11:30:58Z","timestamp":1726227058000},"page":"1107-1114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-6659","authenticated-orcid":false,"given":"Quoc Riccardo","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ventin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dell\u2019Atti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2233-0903","authenticated-orcid":false,"given":"Marzia","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Butturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-1430","authenticated-orcid":false,"given":"Filippo","family":"Crim\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5289-9925","authenticated-orcid":false,"given":"Salvatore","family":"Pucciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina R.","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaya","family":"Spolverato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2024.09.010_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.pan.2024.09.010_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fonc.2020.00245","article-title":"Neoadjuvant treatment in pancreatic cancer","volume":"10","author":"Oba","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000005433","article-title":"Prediction of r status in resections for pancreatic cancer using simplified radiological criteria","volume":"276","author":"Bolm","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","article-title":"Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with folfirinox","volume":"269","author":"Michelakos","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib6","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1245\/s10434-018-6512-8","article-title":"Folfirinox versus gemcitabine\/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma","volume":"25","author":"Dhir","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamasurg.2020.2286","article-title":"Response and survival associated with first-line folfirinox vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma","volume":"155","author":"Perri","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction folfirinox improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An ageo-French multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000003468","article-title":"Survival outcomes associated with clinical and pathological response following neoadjuvant folfirinox or gemcitabine\/nab-paclitaxel chemotherapy in resected pancreatic cancer","author":"Macedo","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.hpb.2020.01.013","article-title":"Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes","volume":"22","author":"Cloyd","year":"2020","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.pan.2024.09.010_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/SLA.0000000000003570","article-title":"Recurrence in patients achieving pathological complete response after neoadjuvant treatment for advanced pancreatic cancer","volume":"274","author":"Blair","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.surg.2017.11.027","article-title":"Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: the impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy","volume":"163","author":"Blair","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.pan.2024.09.010_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pan.2023.02.005","article-title":"Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma","author":"Bao","year":"2023","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2024.09.010_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.pan.2024.09.010_bib15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.amjsurg.2020.11.035","article-title":"Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer","volume":"221","author":"Hue","year":"2021","journal-title":"Am J Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.pan.2024.09.010_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.pan.2024.09.010_bib18","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2522\/ptj.20130627","article-title":"Introduction to the grade approach for guideline development: considerations for physical therapist practice","volume":"94","author":"Austin","year":"2014","journal-title":"Phys Ther"},{"key":"10.1016\/j.pan.2024.09.010_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2021.12.473","article-title":"Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response","author":"Barrak","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib20","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1245\/s10434-021-11202-8","volume":"29","author":"Hill","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib21","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.surg.2021.10.015","article-title":"Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy","volume":"171","author":"Maeda","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.pan.2024.09.010_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","article-title":"Neoadjuvant radiotherapy after (m)folfirinox for borderline resectable pancreatic adenocarcinoma: a taps consortium study","volume":"20","author":"Janssen","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.pan.2024.09.010_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mfolfirinox vs mfolfirinox plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the a021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4149\/neo_2023_230409N193","article-title":"Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"70","author":"Argal\u00e1csov\u00e1","year":"2023","journal-title":"Neoplasma"},{"key":"10.1016\/j.pan.2024.09.010_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjsurg.2023.10.053","article-title":"Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma","volume":"232","author":"Akumuo","year":"2024","journal-title":"Am J Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/00031348241250043","article-title":"Neoadjuvant chemotherapy and radiation improves recurrence-free and overall survival in resectable and borderline resectable pancreatic ductal adenocarcinoma","author":"Kelley","year":"2024","journal-title":"Am Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17625","article-title":"Pathological complete response in patients with resected pancreatic adenocarcinoma after preoperative chemotherapy","volume":"7","author":"Stoop","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pan.2024.09.010_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/bjs\/znac350","article-title":"Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (isgpp-1)","volume":"110","author":"Janssen","year":"2022","journal-title":"Br J Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib29","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s11605-020-04697-1","article-title":"Is complete pathologic response in pancreatic cancer overestimated? A systematic review of prospective studies","volume":"24","author":"Laura","year":"2020","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib30","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"1","author":"Truty","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.pan.2024.09.010_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.surg.2019.12.008","article-title":"Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy","volume":"167","author":"Maeda","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.pan.2024.09.010_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant folfirinox versus upfront surgery for resectable pancreatic head cancer (norpact-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2024.09.010_bib33","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1245\/s10434-020-09391-9","article-title":"Outcomes of neoadjuvant chemotherapy versus chemoradiation in localized pancreatic cancer: a case-control matched analysis","volume":"28","author":"Chopra","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1245\/s10434-018-07131-8","article-title":"Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery","volume":"26","author":"Nagakawa","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pan.2024.09.010_bib35","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.pan.2020.07.375","article-title":"Neoadjuvant radiation therapy does not increase survival and may increase post-operative mortality in the treatment of pancreatic cancer","volume":"20","author":"Oba","year":"2020","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2024.09.010_bib36","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the lap07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324007427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390324007427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T15:35:48Z","timestamp":1731166548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390324007427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1424390324007427"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2024.09.010","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 IAP and EPC. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}